An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
NCT02676401
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
241
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Nephropathy
Interventions
DRUG:
MT-3995 Low
DRUG:
MT-3995 Middle
DRUG:
MT-3995 High
Sponsor
Tanabe Pharma Corporation